ClinicalTrials.gg
RecruitingNCT05918861dal-GenE-2Updated Jun 22, 2026

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

A Phase 3 interventional study of Dalcetrapib and Placebo in Acute Coronary Syndrome, sponsored by DalCor Pharmaceuticals. Recruiting at 231 sites in 3 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by DalCor Pharmaceuticals · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 265 studies in Acute Coronary Syndrome with a site in United States — 14 open to participants now, 21 under way, 2 of them phase 3. Acute Coronary Syndrome · United States.

Planned enrollment
37th of 186
2,000 · median 150
Started
2023
with 5 others
Phase 3
40 of 265
1 open now
Primary completion
2027-08
later than 14 of 20 live
Registered
250th of 265
by date

Among the 265 studies in Acute Coronary Syndrome with a site in United States, this one is the 37th largest by planned enrollment of the 186 interventional ones that give a count, is one of 6 that started in 2023, is one of 40 in phase 3, reaches primary completion later than 14 of the 20 other live ones, and was the 250th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

14 of the 265 studies in Acute Coronary Syndrome with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Acute Coronary Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may begin in the hospital and will continue following release from the hospital or may begin following release from hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (up to12 weeks after the index event). Subjects will be assessed based on their medical history. Those who are likely to qualify will undergo Genotype Assay testing to evaluate genetic determination for the presence of AA genotype.

Read the detailed description

This is an event-driven study and will last until approximately 200 subjects have experienced a primary event, unless the study is stopped at the planned interim analysis. Visits after randomization will be performed as virtual visits where permissible every 3 months or as clinic visits until the study is stopped. For any subject prematurely discontinuing study medication, assessments will be conducted every 3 months for the collection of study endpoints.

Those who are likely to qualify will undergo Genotype Assay Testing to evaluate genetic determination or the presence of the AA genotype at variant rs 1967309 in the ADCY9 gene as determined by the investigational use only version of the cobas ADCY9 Genotype Test, conducted at a designated investigational testing site.

03

Conditions studied

  • Acute Coronary Syndrome
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with the appropriate genetic background and recently hospitalized for ACS (up to 3 months following the index event), will be enrolled in this trial.
  • Both male and female subjects age 45 years and over at screening visit (V1)
  • AA genotype at variant gene as determined by Genotype Assay Test, conducted at a designated testing site (ITS)
  • Clinically stable, ie, free of ischemic symptoms at rest or with minimal exertion for at least 1 week prior to randomization
  • Prior to randomization, subjects must have evidence of guidelines-based management of LDL-C, at a minimum to include medical and dietary treatment.
  • Randomization within 3 months of the index ACS event

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant (negative urine pregnancy test required for all women of at Visit 2, Day 0) or breast-feeding
  • Women of childbearing potential (women who are not surgically sterile or defined as amenorrhea for >12 months) who are not using at least one highly effective method of .
  • (NYHA) Class III or IV heart failure
  • Index ACS event presumed due to uncontrolled hypertension
  • Systolic blood pressure (BP) >180 mmHg and/or diastolic blood pressure >110 mmHg at the time of randomization despite anti-hypertensive therapy
  • Subjects with clinically apparent liver disease, eg, jaundice, cholestasis, hepatic synthetic impairment, active hepatitis or last known or AST level >3 x within 6 months prior to randomization (excluding index event)
  • History of persistent and unexplained creatine phosphokinase (CPK) levels > 5 times the ULN as assessed within 6 months prior to randomization (excluding index event)
  • Last known \< 30 mL/min/1.73m2 as assessed within 6 months prior to randomization
  • History of or any other significant comorbidity, the prognosis or management of which is likely to interfere with study conduct or subjects with a of less than 3 years.
  • Presence of any last known laboratory value as evaluated prior to randomization that is considered by the investigator to potentially limit the patient's successful participation in the study
  • Subjects who have received any drug within 1 month of randomization, or who expect to participate in any other investigational drug or device study during the conduct of this trial
  • Subjects who have undergone coronary artery bypass graft (CABG) surgery between the index event and randomization
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    Dalcetrapib

    Dalcetrapib 600 mg (two 300 mg tablets) orally once daily

    Drug: Dalcetrapib

  • Placebo comparator
    Placebo

    Matching dalcetrapib placebo tablets (2 tablets) orally once per day

    Drug: Placebo

Interventions

  • Cholesterol Ester Transfer Protein Inhibitor, 300 mg tablets

    Also known as: Cholesterol Ester Transfer Protein Inhibitor

  • DrugPlacebo

    matching placebo tablets

    Also known as: Dalcetrapib matching placebo tablets

06

What researchers measure

Primary outcomes

  1. Time to first occurrence of any fatal or non-fatal myocardial infarction (MI)

    Time to patients experiencing major cardiovascular events

    Time frame: Average of 30 months from randomization

Secondary outcomes

  1. The composite of all-cause death, resuscitated cardiac arrest, non-fatal MI and non-fatal stroke

    Time to patients experiencing major cardiovascular events

    Time frame: Average of 30 months from randomization

  2. Composite of all-cause death, resuscitated cardiac arrest, non-fatal MI and non-fatal stroke

    Time to patients experiencing first and recurrent occurrences

    Time frame: Average of 30 months from randomization

  3. Fatal and non-fatal MI

    Time to patients experiencing first and recurrent occurrences

    Time frame: Average of 30 months from randomization

07

Study locations

157 of 231 sites recruiting
  • Research Site
    Alexander City, Alabama 35010, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Birmingham, Alabama 35211, United States
    Recruiting
  • Research Site
    Fairhope, Alabama 36532, United States
    Recruiting
  • Research Site
    Huntsville, Alabama 35801, United States
    Recruiting
  • Research Site
    Mobile, Alabama 36608, United States
    Recruiting
  • Research Site
    Scottsdale, Arizona 85258, United States
    Recruiting
  • Research Site
    Tucson, Arizona 85724, United States
    Recruiting
  • Research Site
    Jonesboro, Arkansas 72405, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    North Little Rock, Arkansas 72117, United States
    Recruiting
  • Research Site
    Garden Grove, California 92844, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Huntington Beach, California 92648, United States
    Recruiting
  • Research Site
    La Jolla, California 92037, United States
    Recruiting
  • Research Site
    Long Beach, California 90813, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Los Angeles, California 90025, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Newport Beach, California 92648, United States
    Not yet recruiting
  • Research Site
    Newport Beach, California 92658, United States
    Not yet recruiting
  • Research Site
    San Francisco, California 94143, United States
    Recruiting
  • Research Site
    Santa Barbara, California 93105, United States
    Recruiting
  • Research Site
    Stanford, California 94305, United States
    Recruiting
  • Research Site
    Torrance, California 90502, United States
    Recruiting
  • Research Site
    West Hills, California 91307, United States
    Recruiting
  • Research Site
    Aurora, Colorado 80011, United States
    Recruiting
  • Research Site
    Golden, Colorado 80401, United States
    Recruiting
  • Research Site
    Hartford, Connecticut 06102, United States
    Recruiting
  • Research Site
    New Haven, Connecticut 06519, United States
    Recruiting
  • Research Site
    Newark, Delaware 19718, United States
    Recruiting
  • Research Site
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Research Site
    Boca Raton, Florida 33434, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Boca Raton, Florida 33486, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Research Site
    Clearwater, Florida 33756, United States
    Recruiting
  • Research Site
    Doral, Florida 33166, United States
    Not yet recruiting
  • Research Site
    Fort Lauderdale, Florida 33316, United States
    Recruiting
  • Research Site
    Fort Myers, Florida 33908, United States
    Recruiting
  • Research Site
    Gainesville, Florida 32608, United States
    Not yet recruiting
  • Research Site
    Hialeah, Florida 33013, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Homestead, Florida 33030, United States
    Recruiting
  • Research Site
    Jacksonville, Florida 32209, United States
    Recruiting
  • Research Site
    Kissimmee, Florida 34741, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Largo, Florida 33777, United States
    Recruiting
  • Research Site
    Miami, Florida 33032, United States
    Recruiting
  • Research Site
    Miami, Florida 33033, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Miami, Florida 33136, United States
    Recruiting
  • Research Site
    Miami, Florida 33145, United States
    Recruiting
  • Research Site
    Miami, Florida 33175, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Miami Lakes, Florida 33014, United States
    Recruiting
  • Research Site
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Research Site
    Ocala, Florida 34471, United States
    Recruiting
  • Research Site
    Orlando, Florida 32803, United States
    Not yet recruiting
  • Research Site
    Pembroke Pines, Florida 33024, United States
    Recruiting
  • Research Site
    Pensacola, Florida 32502, United States
    Not yet recruiting
  • Research Site
    Port Charlotte, Florida 33952, United States
    Recruiting
  • Research Site
    Safety Harbor, Florida 34695, United States
    Recruiting
  • Research Site
    Sarasota, Florida 34239, United States
    Recruiting
  • Research Site
    South Miami, Florida 33143, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Tallahassee, Florida 32308, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Tampa, Florida 33606, United States
    Recruiting
  • Research Site
    Tampa, Florida 33607, United States
    Recruiting
  • Research Site
    The Villages, Florida 32162, United States
    Not yet recruiting
  • Research Site
    Winter Haven, Florida 33881, United States
    Recruiting
  • Research Site
    Acworth, Georgia 30101, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Atlanta, Georgia 30310, United States
    Recruiting
  • Research Site
    Atlanta, Georgia 30322, United States
    Recruiting
  • Research Site
    Augusta, Georgia 30912, United States
    Recruiting
  • Research Site
    Gainesville, Georgia 30501, United States
    Not yet recruiting
  • Research Site
    McDonough, Georgia 30253, United States
    Recruiting
  • Research Site
    Arlington Heights, Illinois 60005, United States
    Recruiting
  • Research Site
    Bloomingdale, Illinois 60108, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Chicago, Illinois 60612, United States
    Not yet recruiting
  • Research Site
    Chicago, Illinois 60616, United States
    Recruiting
  • Research Site
    Glenview, Illinois 60026, United States
    Recruiting
  • Research Site
    Hazel Crest, Illinois 60429, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Park Ridge, Illinois 60068, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Springfield, Illinois 62702, United States
    Recruiting
  • Research Site
    Fort Wayne, Indiana 46845, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Indianapolis, Indiana 46202, United States
    Recruiting
  • Research Site
    Merrillville, Indiana 46410, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Munster, Indiana 46321, United States
    Recruiting
  • Research Site
    Newburgh, Indiana 47630, United States
    Recruiting
  • Research Site
    Richmond, Indiana 47374, United States
    Recruiting
  • Research Site
    Davenport, Iowa 52801, United States
    Recruiting
  • Research Site
    Iowa City, Iowa 52242, United States
    Recruiting
  • Research Site
    West Des Moines, Iowa 50266, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Kansas City, Kansas 66160, United States
    Recruiting
  • Research Site
    Edgewood, Kentucky 41017, United States
    Not yet recruiting
  • Research Site
    Lexington, Kentucky 40536, United States
    Recruiting
  • Research Site
    Louisville, Kentucky 40202, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Hammond, Louisiana 70403, United States
    Recruiting
  • Research Site
    Lafayette, Louisiana 70503, United States
    Recruiting
  • Research Site
    Mandeville, Louisiana 70448, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    New Orleans, Louisiana 70121, United States
    Recruiting
  • Research Site
    Bangor, Maine 04401, United States
    Recruiting
  • Research Site
    Baltimore, Maryland 21215, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Bethesda, Maryland 20814, United States
    Recruiting
  • Research Site
    Bowie, Maryland 20715, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Columbia, Maryland 21044, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Lutherville, Maryland 21093, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Bay City, Michigan 48708, United States
    Recruiting
  • Research Site
    Dearborn, Michigan 48126, United States
    Recruiting
  • Research Site
    Detroit, Michigan 48202, United States
    Recruiting
  • Research Site
    Kalamazoo, Michigan 49048, United States
    Recruiting

Showing the first 100 of 231 sites across 3 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Aug 2027, 46 months after the start.

Of 39 phase 3 interventional studies under Acute Coronary Syndrome, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's planned 46 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2023
First posted
Jun 26, 2023
StartActual
Oct 3, 2023
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05918861
Lead sponsor
DalCor Pharmaceuticals
Collaborators
The Montreal Health Innovations Coordinating Center (MHICC)
Responsible party
Sponsor
First posted
Jun 26, 2023
Start date
Oct 3, 2023
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Jun 22, 2026

Study contacts

David Kallend, MBBS
Contact
dkallend@dalcorpharma.com
+41 79 174 1830
Therese Heinonen, DVM
Contact
theinonen@dalcorpharma.com
David Kallend, MBBS
study director · DalCor

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dalcetrapib

Start the discussion